220 related articles for article (PubMed ID: 35209175)
1. Prediction of Monomeric and Dimeric Structures of CYP102A1 Using AlphaFold2 and AlphaFold Multimer and Assessment of Point Mutation Effect on the Efficiency of Intra- and Interprotein Electron Transfer.
Ivanov YD; Taldaev A; Lisitsa AV; Ponomarenko EA; Archakov AI
Molecules; 2022 Feb; 27(4):. PubMed ID: 35209175
[TBL] [Abstract][Full Text] [Related]
2. Cryo-EM reveals the architecture of the dimeric cytochrome P450 CYP102A1 enzyme and conformational changes required for redox partner recognition.
Su M; Chakraborty S; Osawa Y; Zhang H
J Biol Chem; 2020 Feb; 295(6):1637-1645. PubMed ID: 31901079
[TBL] [Abstract][Full Text] [Related]
3. The full-length cytochrome P450 enzyme CYP102A1 dimerizes at its reductase domains and has flexible heme domains for efficient catalysis.
Zhang H; Yokom AL; Cheng S; Su M; Hollenberg PF; Southworth DR; Osawa Y
J Biol Chem; 2018 May; 293(20):7727-7736. PubMed ID: 29618513
[TBL] [Abstract][Full Text] [Related]
4. Flavocytochrome P450 BM3 mutant W1046A is a NADH-dependent fatty acid hydroxylase: implications for the mechanism of electron transfer in the P450 BM3 dimer.
Girvan HM; Dunford AJ; Neeli R; Ekanem IS; Waltham TN; Joyce MG; Leys D; Curtis RA; Williams P; Fisher K; Voice MW; Munro AW
Arch Biochem Biophys; 2011 Mar; 507(1):75-85. PubMed ID: 20868649
[TBL] [Abstract][Full Text] [Related]
5. Glutamate-haem ester bond formation is disfavoured in flavocytochrome P450 BM3: characterization of glutamate substitution mutants at the haem site of P450 BM3.
Girvan HM; Levy CW; Williams P; Fisher K; Cheesman MR; Rigby SE; Leys D; Munro AW
Biochem J; 2010 Apr; 427(3):455-66. PubMed ID: 20180779
[TBL] [Abstract][Full Text] [Related]
6. Structure, electronic properties and catalytic behaviour of an activity-enhancing CYP102A1 (P450(BM3)) variant.
Whitehouse CJ; Yang W; Yorke JA; Tufton HG; Ogilvie LC; Bell SG; Zhou W; Bartlam M; Rao Z; Wong LL
Dalton Trans; 2011 Oct; 40(40):10383-96. PubMed ID: 21603690
[TBL] [Abstract][Full Text] [Related]
7. Engineering bacterial cytochrome P450 (P450) BM3 into a prototype with human P450 enzyme activity using indigo formation.
Park SH; Kim DH; Kim D; Kim DH; Jung HC; Pan JG; Ahn T; Kim D; Yun CH
Drug Metab Dispos; 2010 May; 38(5):732-9. PubMed ID: 20100815
[TBL] [Abstract][Full Text] [Related]
8. Electron transfer in flavocytochrome P450 BM3: kinetics of flavin reduction and oxidation, the role of cysteine 999, and relationships with mammalian cytochrome P450 reductase.
Roitel O; Scrutton NS; Munro AW
Biochemistry; 2003 Sep; 42(36):10809-21. PubMed ID: 12962506
[TBL] [Abstract][Full Text] [Related]
9. [Electrochemical measurement of intraprorein and interprotein electron transfer].
Shumiantseva VV; Bulko TV; Lisitsina VB; Urlakher VB; Kuzikov AB; Suprun EV; Archakov AI
Biofizika; 2013; 58(3):453-60. PubMed ID: 24159813
[TBL] [Abstract][Full Text] [Related]
10. Scanning chimeragenesis: the approach used to change the substrate selectivity of fatty acid monooxygenase CYP102A1 to that of terpene omega-hydroxylase CYP4C7.
Chen CK; Berry RE; Shokhireva TKh; Murataliev MB; Zhang H; Walker FA
J Biol Inorg Chem; 2010 Feb; 15(2):159-74. PubMed ID: 19727859
[TBL] [Abstract][Full Text] [Related]
11. Generation of human metabolites of 7-ethoxycoumarin by bacterial cytochrome P450 BM3.
Kim DH; Kim KH; Kim DH; Liu KH; Jung HC; Pan JG; Yun CH
Drug Metab Dispos; 2008 Nov; 36(11):2166-70. PubMed ID: 18669587
[TBL] [Abstract][Full Text] [Related]
12. Insights into an efficient light-driven hybrid P450 BM3 enzyme from crystallographic, spectroscopic and biochemical studies.
Spradlin J; Lee D; Mahadevan S; Mahomed M; Tang L; Lam Q; Colbert A; Shafaat OS; Goodin D; Kloos M; Kato M; Cheruzel LE
Biochim Biophys Acta; 2016 Dec; 1864(12):1732-1738. PubMed ID: 27639964
[TBL] [Abstract][Full Text] [Related]
13. Kinetics and activation parameters for oxidations of styrene by Compounds I from the cytochrome P450(BM-3) (CYP102A1) heme domain and from CYP119.
Yuan X; Wang Q; Horner JH; Sheng X; Newcomb M
Biochemistry; 2009 Sep; 48(38):9140-6. PubMed ID: 19708688
[TBL] [Abstract][Full Text] [Related]
14. Mapping protein-protein interactions in homodimeric CYP102A1 by crosslinking and mass spectrometry.
Felker D; Zhang H; Bo Z; Lau M; Morishima Y; Schnell S; Osawa Y
Biophys Chem; 2021 Jul; 274():106590. PubMed ID: 33894563
[TBL] [Abstract][Full Text] [Related]
15. Structural analysis of Cytochrome P450 BM3 mutant M11 in complex with dithiothreitol.
Frydenvang K; Verkade-Vreeker MCA; Dohmen F; Commandeur JNM; Rafiq M; Mirza O; Jørgensen FS; Geerke DP
PLoS One; 2019; 14(5):e0217292. PubMed ID: 31125381
[TBL] [Abstract][Full Text] [Related]
16. Control of the stereo-selectivity of styrene epoxidation by cytochrome P450 BM3 using structure-based mutagenesis.
Huang WC; Cullis PM; Raven EL; Roberts GC
Metallomics; 2011 Apr; 3(4):410-6. PubMed ID: 21240430
[TBL] [Abstract][Full Text] [Related]
17. Role of residue 87 in substrate selectivity and regioselectivity of drug-metabolizing cytochrome P450 CYP102A1 M11.
Vottero E; Rea V; Lastdrager J; Honing M; Vermeulen NP; Commandeur JN
J Biol Inorg Chem; 2011 Aug; 16(6):899-912. PubMed ID: 21567268
[TBL] [Abstract][Full Text] [Related]
18. A highly active single-mutation variant of P450BM3 (CYP102A1).
Whitehouse CJ; Bell SG; Yang W; Yorke JA; Blanford CF; Strong AJ; Morse EJ; Bartlam M; Rao Z; Wong LL
Chembiochem; 2009 Jul; 10(10):1654-6. PubMed ID: 19492389
[TBL] [Abstract][Full Text] [Related]
19. Probing the molecular determinants of coenzyme selectivity in the P450 BM3 FAD/NADPH domain.
Dunford AJ; Girvan HM; Scrutton NS; Munro AW
Biochim Biophys Acta; 2009 Aug; 1794(8):1181-9. PubMed ID: 19344791
[TBL] [Abstract][Full Text] [Related]
20. The effect of mutation of F87 on the properties of CYP102A1-CYP4C7 chimeras: altered regiospecificity and substrate selectivity.
Chen CK; Shokhireva TKh; Berry RE; Zhang H; Walker FA
J Biol Inorg Chem; 2008 Jun; 13(5):813-24. PubMed ID: 18392864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
